Immunotherapy with chemotherapy for advanced bile duct cancer
Part of Cancer clinical trials.
This trial tests a combination of two immunotherapy drugs with chemotherapy for people with advanced bile duct cancer that cannot be removed by surgery or has spread. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with a type of bile duct cancer called intrahepatic cholangiocarcinoma that is advanced or has spread, and it cannot be removed by surgery.
- You have not received any prior treatment for advanced or metastatic disease, such as chemotherapy, targeted therapy, or immunotherapy.
- You have at least one tumor that can be measured on a scan.
- You are generally able to care for yourself (ECOG performance status 0 or 1).
- Your liver, kidney, and blood cell counts are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug combined with standard chemotherapy as a first treatment for advanced bile duct or gallbladder cancer. It may help your immune system fight the cancer while chemotherapy attacks the tumor directly.
This Phase 3 study tests whether toripalimab (an immunotherapy) combined with lenvatinib and chemotherapy works better than standard treatment for advanced intrahepatic cholangiocarcinoma. It aims to help people live longer and/or control the cancer more effectively.
This trial tests a new combination of chemotherapy (gemcitabine and cisplatin), radiation, and an immunotherapy drug called sintilimab for people with first-time intrahepatic cholangiocarcinoma. The goal is to see if this combination shrinks tumors and helps people live longer.
This Phase 2 trial tests whether a procedure called TACE combined with the immunotherapy drug tislelizumab can shrink advanced bile duct liver cancer and help you live longer. It is for people whose cancer cannot be removed and has progressed after at least one prior treatment.
This trial tests a combination of three drugs for bile duct cancer that cannot be removed by surgery: sintilimab (an immunotherapy that helps your immune system fight cancer), bevacizumab (a drug that blocks blood vessel growth to tumors), and a standard chemotherapy called AG (gemcitabine and capecitabine). The goal is to see if this combination can help shrink or control the cancer as a first treatment option.
This Phase 2 trial tests a combination of lenvatinib, an immunotherapy drug (tislelizumab), and chemotherapy (gemcitabine plus cisplatin) for advanced bile duct cancer that cannot be removed with surgery. It aims to see whether this treatment can shrink tumors and improve outcomes, especially for people who have not yet had immunotherapy.
Hear when a new Advanced Intrahepatic Cholangiocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.